Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Study Information
Alliance Study ID: A091304
NCT Study ID (ClinicalTrials.gov): NCT02601209
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Sarcoma & Soft Tissue / Bone Cancers
Alliance Study Chair: William D Tap
Status: TERMINATED
Study Description
This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information